Cohealyx expands AVITA Medical’s therapeutic wound care portfolio, complementing its flagship product, the RECELL ® System, which is FDA-approved for the treatment of thermal burns and full-thickness ...
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback